UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 Current Report
                     Pursuant To Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported) OCTOBER 27, 2004

                            PSYCHEMEDICS CORPORATION
             (Exact Name of Registrant As Specified In Its Charter)

                                    DELAWARE
                 (State if Other Jurisdiction of Incorporation)

                1-13738                                  58-1701987
        (Commission File Number)            (I.R.S. Employer Identification No.)


  125 NAGOG PARK, ACTON, MASSACHUSETTS                     01720
(Address of Principal Executive Offices)                (Zip Code)

                                 (978) 206-8220
              (Registrant's Telephone Number, Including Area Code)


             1280 MASSACHUSETTS AVE., SUITE 200, CAMBRIDGE, MA 02138
          (Former name or former address, if changed since last report)


     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_| Written communications pursuant to Rule 425 under the Securities Act
         (17 CFR 230.425)

     |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
         CFR 240.14a-12)

     |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
         Exchange Act (17 CFR 240.14d-2(b))

     |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
         Exchange Act (17 CFR 240.13e-4(c))




ITEM 2.02   RESULTS OF OPERATIONS AND FINANCIAL CONDITION

         On October 27, 2004, Psychemedics Corporation issued a press release
announcing preliminary results for the quarter ended September 30, 2004. A copy
of the press release is attached hereto as Exhibit 99.1 and incorporated by
reference herein.

         LIMITATION ON INCORPORATION BY REFERENCE. The information in this Form
8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or
otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933 or the
Exchange Act, regardless of any general incorporation language in such filing.

         CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS. Except for
historical information contained in the press release attached as an exhibit
hereto, the press release contains forward-looking statements which involve
certain risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by these statements. Please refer to
the cautionary note in the press release regarding these forward-looking
statements.

ITEM 9.01   FINANCIAL STATEMENTS, PRO-FORMA FINANCIAL INFORMATION AND EXHIBITS.


            (c)      Exhibits

            The following exhibits are filed herewith:

            99.1     Press Release dated October 27, 2004.




                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                   PSYCHEMEDICS CORPORATION
Dated: October 29, 2004


                                   By:  /s/ Peter C. Monson           
                                       -------------------------------------
                                       Peter C. Monson, Vice President and
                                       Chief Financial Officer





                                  EXHIBIT INDEX

EXHIBIT         
NUMBER         DESCRIPTION

99.1           Press release dated October 27, 2004 of Psychemedics Corporation
               announcing its financial results for the quarter ended September
               30, 2004.